COO icon

Cooper Companies

93.44 USD
+1.51
1.64%
At close Dec 20, 4:00 PM EST
After hours
93.44
+0.00
0.00%
1 day
1.64%
5 days
-1.39%
1 month
-5.69%
3 months
-15.43%
6 months
1.86%
Year to date
0.18%
1 year
3.72%
5 years
17.14%
10 years
128.52%
 

About: CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.

Employees: 16,000

0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

50% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 6 (+2) [Q3]

49% more first-time investments, than exits

New positions opened: 88 | Existing positions closed: 59

22% more capital invested

Capital invested by funds: $17.1B [Q2] → $20.8B (+$3.76B) [Q3]

5% more funds holding

Funds holding: 617 [Q2] → 646 (+29) [Q3]

8% less repeat investments, than reductions

Existing positions increased: 228 | Existing positions reduced: 248

3.18% less ownership

Funds ownership: 98.36% [Q2] → 95.18% (-3.18%) [Q3]

11% less call options, than puts

Call options by funds: $41.9M | Put options by funds: $47.2M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$102
9%
upside
Avg. target
$112
20%
upside
High target
$118
26%
upside

3 analyst ratings

positive
67%
neutral
33%
negative
0%
Citigroup
Joanne Wuensch
55% 1-year accuracy
26 / 47 met price target
23%upside
$115
Buy
Maintained
6 Dec 2024
Morgan Stanley
Patrick Wood
55% 1-year accuracy
6 / 11 met price target
9%upside
$102
Equal-Weight
Maintained
6 Dec 2024
Wells Fargo
Larry Biegelsen
51% 1-year accuracy
24 / 47 met price target
26%upside
$118
Overweight
Maintained
6 Dec 2024

Financial journalist opinion

Based on 10 articles about COO published over the past 30 days

Neutral
GlobeNewsWire
4 days ago
CooperCompanies to Present at the J.P. Morgan Healthcare Conference
SAN RAMON, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, today announced it will participate at the J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. Al White, President and CEO, will represent the Company in a session scheduled to begin at 6:00 PM ET.
CooperCompanies to Present at the J.P. Morgan Healthcare Conference
Neutral
Zacks Investment Research
1 week ago
The Cooper Companies (COO) International Revenue in Focus: Trends and Expectations
Explore how The Cooper Companies' (COO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
The Cooper Companies (COO) International Revenue in Focus: Trends and Expectations
Neutral
Zacks Investment Research
2 weeks ago
Cooper Companies Q4 Earnings Beat, Revenues Miss, Stock Falls
COO's top line fails to meet market expectations despite recording strong growth. However, improvement in operating margin bodes well.
Cooper Companies Q4 Earnings Beat, Revenues Miss, Stock Falls
Neutral
Seeking Alpha
2 weeks ago
The Cooper Companies, Inc. (COO) Q4 2024 Earnings Call Transcript
The Cooper Companies, Inc. (NASDAQ:COO ) Q4 2024 Earnings Conference Call December 5, 2024 5:00 PM ET Company Participants Kim Duncan - Vice President, Investor Relations & Risk Management Albert White - President & Chief Executive Officer Brian Andrews - Chief Financial Officer & Treasurer Conference Call Participants Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Jeffrey Johnson - Baird Jon Block - Stifel Robbie Marcus - JPMorgan Chris Pasquale - Nephron Jason Bednar - Piper Sandler Issie Kirby - Redburn Atlantic Steve Lichtman - Oppenheimer Brett Fishbin - KeyBanc Capital Markets Navann Ty - BNP Paribas Anthony Petrone - Mizuho Operator Ladies and gentlemen, thank you for standing by. My name is Abby, and I will be your conference operator today.
The Cooper Companies, Inc. (COO) Q4 2024 Earnings Call Transcript
Positive
Zacks Investment Research
2 weeks ago
The Cooper Companies (COO) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for The Cooper Companies (COO) give a sense of how its business performed in the quarter ended October 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The Cooper Companies (COO) Reports Q4 Earnings: What Key Metrics Have to Say
Positive
Zacks Investment Research
2 weeks ago
The Cooper Companies (COO) Q4 Earnings Beat Estimates
The Cooper Companies (COO) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $1 per share. This compares to earnings of $0.87 per share a year ago.
The Cooper Companies (COO) Q4 Earnings Beat Estimates
Neutral
GlobeNewsWire
2 weeks ago
CooperCompanies Announces Fourth Quarter and Full Year 2024 Results
SAN RAMON, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal fourth quarter and full year ended October 31, 2024.
CooperCompanies Announces Fourth Quarter and Full Year 2024 Results
Positive
Zacks Investment Research
2 weeks ago
Strong Segmental Sales to Drive Cooper Companies Q4 Earnings?
COO's fiscal fourth-quarter results are likely to reflect segmental strength.
Strong Segmental Sales to Drive Cooper Companies Q4 Earnings?
Positive
Zacks Investment Research
2 weeks ago
Unveiling The Cooper Companies (COO) Q4 Outlook: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for The Cooper Companies (COO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended October 2024.
Unveiling The Cooper Companies (COO) Q4 Outlook: Wall Street Estimates for Key Metrics
Positive
Seeking Alpha
3 weeks ago
Cooper Companies: Is This A Fertility Play Now?
The Cooper Companies have significantly grown its fertility segment with acquisitions in recent years and now boasts a robust portfolio of over 600 products supporting various fertility treatments with a global footprint. Fertility rates are declining globally, with countries implementing policies to boost birth rates, making fertility services increasingly essential. The scale of the issue is often underappreciated. With a track record of organic growth and market share gains in its vision segment, COO looks like a compelling way to play the secular tailwinds for the fertility industry.
Cooper Companies: Is This A Fertility Play Now?
Charts implemented using Lightweight Charts™